Modeling and Simulation - PK/PD Archives | Page 25 of 38 | サターラ

Publication

Prediction of Overall Survival or Progression Free Survival by Disease Control Rate at Week 8 Is Independent of Ethnicity: Western Versus Chinese Patients with First-line Non-small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab

Categorizations of best response observed at week 8 of first-line treatment in two studies of…

Certara2013年10月22日

Knowledge Base

Using Sampling “Windows” for PK Blood Samples

One of the most common questions posed by clinical operations experts when including pharmacokinetic sampling…

Certara2013年10月15日

Publication

Effect of Meal and Antisecretory Agents on the Pharmacokinetics of Danoprevir/Ritonavir in Healthy Volunteers

Certara2013年10月10日

Publication

Influence of Chronic Hepatitis C Infection on Cytochrome P450 3A4 Activity Using Midazolam as an In Vivo Probe Substrate

Certara2013年10月1日

Publication

Differential Pharmacokinetics of Ganitumab in Patients with Metastatic Pancreatic Cancer Versus Other Advanced Solid Cancers

Ganitumab is an investigational, fully human monoclonal antibody antagonist of the insulin-like growth factor-1 receptor…

Certara2013年10月1日

Publication

Exposure-response Analysis of Pertuzumab in HER2-positive Metastatic Breast Cancer: Absence of Effect on QTc Prolongation and Other ECG Parameters

The phase III trial of pertuzumab plus trastuzumab plus docetaxel versus placebo plus trastuzumab plus…

Certara2013年9月3日

Publication

Pharmacokinetics of a Three-way Drug Interaction Between Danoprevir, Ritonavir, and the Organic Anion Transporting Polypeptide (OATP) Inhibitor Ciclosporin

Certara2013年9月1日

Publication

Application of Permeability-limited Physiologically-based Pharmacokinetic Models: Part I—Digoxin Pharmacokinetic Incorporating P-glycoprotein-mediated Efflux

A prerequisite for the prediction of the magnitude of P-glycoprotein (P-gp)-mediated drug-drug interactions between digoxin…

Certara2013年9月1日

Publication

Application of Permeability-limited Physiologically-based Pharmacokinetic Models: Part II—Prediction of P-glycoprotein Mediated Drug-drug Interactions with Digoxin

Digoxin is the recommended substrate for assessment of P-glycoprotein (P-gp)-mediated drug-drug interactions (DDIs) in vivo.…

Certara2013年9月1日

Publication

Siponimod for Patients with Relapsing-remitting Multiple Sclerosis (BOLD): An Adaptive, Dose-ranging, Randomized, Phase 2 Study

Siponimod is an oral selective modulator of sphingosine 1-phosphate receptor types 1 and type 5,…

Certara2013年9月1日

© 2025 Certara. All Rights Reserved. | 個人情報保護

Powered by Translations.com GlobalLink Web Software